ArriVent BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '25 May 13, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	653	898	-	-	-
Enterprise Value	478	615	-	-	-
Last Close Price	19.10	26.64	-	-	-
PB Ratio	3.21	3.48	-	-	-
P/TBV Ratio	3.23	3.48	-	-	-
Debt / Equity Ratio	0.00	0.00	0.00	0.00	-
Quick Ratio	13.63	12.70	13.00	19.60	20.64
Current Ratio	14.34	13.14	13.76	21.85	23.63
Return on Equity (ROE)	-49.00%	-39.36%	-42.57%	-34.22%	-
Return on Assets (ROA)	-23.10%	-26.91%	-26.95%	-20.42%	-
Return on Capital (ROIC)	-24.10%	-28.79%	-28.58%	-21.38%	-
Earnings Yield	-19.51%	-8.97%	-	-	-
Buyback Yield / Dilution	-316.83%	-1369.88%	-67.64%	-79.57%	-

Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q